CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04925986
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:35.842952+00:00
Published At: 2025-04-17T00:00:00+00:00
Record Updated At: 2025-04-17
Results Posted At: 2025-04-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Carcinoma, Non-Small-Cell Lung", "Lung Diseases", "Lung Neoplasms", "Metastatic Lung Non-Small Cell Carcinoma", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "PD-L1 Gene Mutation", "Advanced Treatment-Na\u00efve PD-L1", "Sitravatinib", "Pembrolizumab"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-17"
protocolSection.identificationModule.nctId: "NCT04925986"
protocolSection.identificationModule.officialTitle: "Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Na\u00efve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-04-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.